MD, addicted to receptor pharmacology

Joined May 2020
I am so happy that our paper on the spatiotemporal bias in beta-arrestin signaling is finally out in @scisignal! In this short tweetorial, I would like to sum up the main findings. 🧵doi.org/10.1126/scisignal.ad…
1
6
1
27
2,514
I am delighted to report that our latest paper has now been published in Science Advances: science.org/doi/10.1126/scia… In this study, we generated and characterised a humanised GLP‑1R mouse model carrying the gain‑of‑function A316T variant using CRISPR/Cas9 knock‑in technology.
2
11
1
23
1,154
Hooray!! The first major product from the lab is out today @Nature. Small molecules that bind the GPCR-transducer interface change G protein subtype selectivity in predictable ways, enabling rational drug design.💥 Check it out! 👉nature.com/articles/s41586-0… 🧵👇
13
49
6
265
28,461
Our latest review in Eur J Pharm Sci summarizes recent advances (2018–2024) in #fluorescent probe development for Class A #GPCRs, analyzing over 120 newly developed probes covering 60 GPCRs. doi.org/10.1016/j.ejps.2025.…
1
2
62
Our new photoaffinity labelling technology (bit.ly/4kiVZ74) is published in @angew_chem. It is more biocompatible, more efficienct, cheaper and easily accessible, even as a late-stage modification. We are working with @EnamineLtd to make it available for the community.
1
3
52
András Tóth retweeted
We are depositing the following mice to @MMRRC Adgrf5-EGFP-CT-IRES-CRE GPR123- EGFP-CT-IRES-CRE GPR124- EGFP-CT-IRES-CRE GPR125- EGFP-CT-IRES-CRE Gpr133-EGFP-CT-IRES-CRE GPR156-IRES-Cre GPR156-mGL-IRES-Cre GPR75-IRES-Cre Bai1 mGL-CT-IRES-Cre GPRC5A- EGFP-CT-IRES-ERT2-CRE 1/2
1
27
1
58
9,740
András Tóth retweeted
Delighted to share our study on promiscuous chemokine binding at a chemokine receptor, now published in @MolecularCell!!! Molecular basis of promiscuous chemokine binding and structural mimicry at the C-X-C chemokine receptor, CXCR2: Molecular Cell cell.com/molecular-cell/full…
17
31
8
197
15,509
András Tóth retweeted
Receptors are essential for cell communication, yet most comp CCC tools focus on ligand/receptor expression, not receptor activity. To address this, we developed RIDDEN, a model that infers activity for 229 receptors from transcriptomics data. 1/ n biorxiv.org/content/10.1101/… 1/n
2
2
4
338
Our perspectives on the various aspects of bias in GPCR function, with a special focus on their relevance to the kidney, have been published in @NatRevNeph. nature.com/articles/s41581-0…
4
1
11
660
Astonishingly, differences in beta-arrestin recruitment almost completely disappeared without endocytosis. Since beta-arrestins form stable interaction with AT1R, even at endosomes, we speculated that agonist-specific differences occur endosomally.
1
1
136
To get a broader picture, @ben_szalai built an ODE-based mathematical model. This model verified the role of ligand k_off and revealed that compartment-specific differences in GPCR phosphorylation/dephosphorylation are crucial for ligand k_off effects to emerge.
1
1
1
152
We hope that the improved understanding of biased signaling will aid in the development of better biased compounds.
112
Why is that so? Since differences in agonist effects developed over a relatively long time, we hypothesized that receptor endocytosis might account for it. We then checked what happens in the absence of endocytosis.
1
109
We measured the transducer activation profile of various AT1 angiotensin receptor agonists in real time with BRET sensors. We found substantial temporal variance in agonist effects for beta-arrestin recruitment but not for G protein activation.
1
137
A new paper shows that the #endocytosis of #GPCRs such as AT1R can influence biased signaling through #BetaArrestin, suggesting the efficacy of beta-arrestin-binding ligands depends on spatial location as much as on receptor conformation. @semmelweishu scim.ag/7th
3
5
547